Progress of targeted therapy in multiple myeloma / 白血病·淋巴瘤

ABSTRACT

Multiple myeloma (MM), the second malignancy of the hematological system, is still untreatable. With the continuous advent of novel targeted therapies, new treatment strategies for MM patients altered, response rate and mitigation depth have also been greatly improved. At the 59th American Society of Hematology (ASH) Annual Meeting, a number of bio-targeted therapies for MM were updated, especially with the combination of various new agents and cell biology therapy. Combined with reports in the 59th ASH Annual Meeting, this paper summarizes the progress of targeted therapy in MM.